Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 May 6;17(5):e0267986. doi: 10.1371/journal.pone.0267986

Alterations in innate immune responses of patients with chronic rhinosinusitis related to cystic fibrosis

Gustavo L Rezende 1,2,3,*,#, Marcio Nakanishi 2,4,5,#, Shirley C P Couto 2, Carmen L F S Martins 2,6, André L L Sampaio 4, Lucas F F Albuquerque 3, Selma A S Kückelhaus 2,3, Maria I Muniz-Junqueira 2,3
Editor: Mrinmoy Sanyal7
PMCID: PMC9075614  PMID: 35522627

Abstract

The role of phagocytes of children with cystic fibrosis (CF) associated with different phenotypes of chronic rhinosinusitis (CRS) is unclear. The aim of this study was to evaluate the phagocytic capacity of blood neutrophils and monocytes and production of superoxide anion by phagocytes in patients with CF with or without chronic rhinosinusitis and with or without nasal polyps (NP). This cross-sectional study was established in 2015–2017 in a tertiary reference center to the CF treatment, Brasilia, Brazil. Sample included 30 children volunteers with CRS related to CF (n = 16) and control subjects (n = 14). Epidemiological and clinical data were compared. Collection of 15 mL of peripheral blood and nasal endoscopy to identify the presence or absence of nasal polyps (NP) were performed. Phagocytosis of Saccharomyces cerevisiae by pathogen-associated molecular pattern receptors and opsonin receptors was assessed. Superoxide anion production was evaluated. The control group showed a higher phagocytic index to monocytes and neutrophils than to the CF or CF+CRS with NP groups [Kruskal-Wallis p = 0.0025] when phagocytosis were evaluated by pathogen-associated molecular pattern receptors (5 yeasts/cell). The phagocytic index of the CF+CRS without NP group was higher than in the CF+CRS with NP group (Kruskal-Wallis p = 0.0168). In the control group, the percentage of phagocytes involved in phagocytosis and superoxide anion production (74.0 ± 9.6%) were higher in all CF groups (p < 0,0001). The innate immune response, represented by phagocytic activity and superoxide anion production by monocytes and neutrophils was more impaired in patients with CF related or not related to CRS than in the control group. However, the phagocytic function of patients without NP showed less impairment.

Introduction

Cystic fibrosis (CF) is characterized by an excessive inflammatory response and the failure to efficiently resolve lung infections, causing major morbidity and mortality [1]. The disease may involve chronic rhinosinusitis (CRS) and nasal polyps (NP). Cystic fibrosis (CF) related CRS causes deficiencies in the phagocytic activity of macrophages and neutrophils [25]. However, it remains unclear whether these changes occur because of the expression of local inflammatory factors or are primary defects depending on CF transmembrane conductance regulator (CFTR) in these leukocytes [610]. NP in children with CRS related to CF is considered as a complication resulting from inflammatory changes in the host [11] or may be a primary manifestation of CF by the inflammatory process before infection, indicating that expression of CFTR has a functional role in monocytes and neutrophils [610].

Local inflammatory changes influence mucociliary clearance and the ability of phagocytes to eliminate invading microorganisms by increasing Na+ and Cl- concentrations in the cell cytosol. A reduction of Cl- in lysosomes [1216] is the main trigger of inflammatory processes in CF, which activate the M1 type of macrophages in CF-NP [17]. CF-NP is associated with upregulation of human β-defensin 2 and Toll-like receptor 2, high tissue infiltration of neutrophils [17] and levels of oxygen species [11]. In patients with CF without NP, expression of the macrophage mannose receptor dominates the innate defense. The inflammation of respiratory tissues leads to the plasticity of macrophage and neutrophil phagocytic activity between a pro-inflammatory, immunogenic, or tissue destructive status or to an anti-inflammatory and tolerogenic phenotype [11].

The genetic basis of CF has been clearly established [17, 18], but no specific mutation is correlated with the impact on the phagocytic activity of neutrophils and monocytes [7, 11] and CF polyp phenotypes. CFTR-like defect has been detected in human monocytes, suggesting that CF macrophage and neutrophil dysfunction is a partial consequence of CFTR defects [1, 10, 19]. Moreover, inhibition of functional CFTR in wild-type macrophages was shown to lead to a phenotype similar to that in CF macrophages [7].

This study was conducted to assess the innate immunity of patients with different CF subtypes. By examining phagocytosis and superoxide anion production [2023], we evaluated whether neutrophils and monocytes that circulate in the peripheral blood participate indirectly in inflammatory activity in the paranasal sinuses [68].

Materials and methods

Patient demographics

This study followed the ethical standards for scientific research on humans in accordance with Law 6,638/79 and was conducted according to the guidelines prescribed by the Declaration of Helsinki [24]. The study was approved by the local Research Ethics Committee (Protocol No. 085/2010). All volunteers and their parents or guardians signed written consent agreeing to the research.

The study included 36 children; their demographic data were collected through a questionnaire at the time of enrollment in a pneumological pediatric clinic of a tertiary hospital in Brazil. The questionnaire assessed the age, gender, presence of nasal symptoms, nutritional status and bacterial colonization status. The nutritional status was classified as a percentile according to the age and normal weight (≥3 and ≤97), malnourished (<3) and overweight (>99,9) [25]. All patients lived in the central area of Brazil. Inclusion criteria were a diagnosis of CF, children >8 or <18 years, and not using any drug except those administered to treat CF. CF was confirmed in children whose chloride level in the sweat test was higher than 60 mmol/L1. The test was performed by placing a pilocarpine solution on the forearm or thigh and stimulating the area with a mild electric current to produce sweating. Subjects with acute respiratory infection, diabetes, an autoimmune disease, severe allergies, renal or gastrointestinal diseases, cancer, anemia or any condition that was considered by the investigators to alter immune system function, including the use of medications that could change the level of inflammatory mediators, were excluded from the study. Children with CF were included in the following groups: CF plus CRS and presenting with NP (CF+CRS with NP, n = 6), CF plus CRS but without NP (CF+CRS without NP, n = 5), and CF without CRS (CF, n = 5). A group of 14 healthy children without CF and without CRS were included as the control group (Table 1).

Table 1. Demographics and characterization of study participants.

Groups Age (years) mean ± SD Pharynx swab (<3 months) Previous surgery Nutritional status Digital clubbing Lund Kennedy endonasal Scale
Control (n = 14) 10 ± 2 - - normal weight no 0.0 ± 0.0
Cystic fibrosis (n = 5) 9 ± 4 Pseudomonas - normal weight no 0.4 ± 0.2
Pseudomonas - malnourished yes
Pseudomonas - malnourished no
Bulkholderia cepacea - malnourished no
Pseudomonas - normal weight yes
CF+CRS with NP (n = 6) 10 ± 2 - ESS normal weight yes 6.4 ± 2.1
Pseudomonas ESS normal weight no
Pseudomonas - normal weight no
Pseudomonas - normal weight yes
Pseudomonas - normal weight no
Staphylococcus liver transplantation# normal weight no
CF+CRS without NP (n = 5) 8 ± 4 Staphylococcus - malnourished yes 0.4 ± 2.2
Pseudomonas - normal weight no
Staphylococcus - malnourished no
Pseudomonas - malnourished no
Pseudomonas - overweight no

CF = Cystic fibrosis; CRS = chronic rhinosinusitis; NP = nasal polyps; ESS: endoscopic sinus surgery; n = 30

# = 8th year after liver transplantation because of congenital biliary atresia, without immunosuppressive drugs at the moment

Healthy children from the control group were recruited from the pediatric clinic and did not present with ear, nose, or throat problems and did not have a family history of CF.

The inclusion criterion for CRS followed the classification based on the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 [2]. CRS was defined as two or more symptoms for over 12 weeks, one of which was nasal blockage or nasal discharge, and ± facial pain/ pressure, ± reduction, or loss of smell or ± cough (children). In addition, endoscopic signs of NP and/or mucopurulent discharge from the middle meatus were necessary to define CRS. All subjects with CF underwent rigid nasal endoscopy examination (zero-degree endoscope, Fiegert Endotech, Fort Lauderdale, FL, USA) and were classified following the methods and criteria proposed by Lund and Kennedy [26] (patients scored using a scale of 0–2 points based on the presence of polyps, edema, discharge, scarring, and crusting).

The participants underwent general clinical and ear, nose, and throat examination, and were subjected to nasal endoscopy. Peripheral blood was collected into 3 sterilized, 5-mL vacuum tubes to measure the phagocytic activities of monocytes and neutrophils as primary outcomes. The secondary outcome was the production of superoxide anion in each group.

Phagocytosis test

Phagocytosis of Saccharomyces cerevisiae was evaluated as previously reported by Muniz-Junqueira et al. with some modifications [21]. Briefly, samples of 40 μL/area of whole peripheral blood were placed on clean glass slides containing 8 marked areas of 7-mm diameter each in duplicate preparations. The slides were incubated in a wet chamber for 45 min at 37°C and then rinsed with 0.15 M phosphate-buffered saline pH 7.2 at 37°C to remove non-adherent cells. After washing, the neutrophils and monocytes remained adhered to the slide in approximately the same proportion as that observed in whole blood (12,534 ± 5050 cells/marked area; 5.63 ± 0.85% monocytes and 93.5 ± 1.08% neutrophils). Adhered cells were incubated with a suspension of 6.5 × 104 (1/5 ratio phagocyte/S. cerevisiae) or 2.5 × 105 S. cerevisiae yeast (1/20 ratio phagocyte/S. cerevisiae) in 20 μL of Hanks-Tris solution (Sigma, St Louis, MO, USA) containing 10% heat-inactivated fetal calf serum (Gibco, Grand Island, NY, USA), pH 7.2, in a wet chamber at 37°C, for 30 min. To evaluate the influence of complement molecules on phagocytosis, S. cerevisiae were sensitized by incubation, at 37°C in 10% fresh serum obtained from the donor samples in Hanks-Tris solution for 30 min. The slides were rinsed with 0.15 M phosphate-buffered saline at 37°C to eliminate non-phagocytosed S. cerevisiae. After washing with Hanks-Tris containing 30% fetal calf serum, the slides were fixed with absolute methanol and stained with Giemsa solution (10%). The phagocytic index (PhI) of 200 monocytes and 200 neutrophils in individual preparations was assessed by optical microscopy (1000x; CH30, Olympus, Tokyo, Japan). Microscopic fields distributed throughout the slide were randomly selected, and all monocytes and all neutrophils in each field were blinded and examined by the same observer. The PhI was calculated as the mean number of phagocytosed S. cerevisiae per phagocytosing monocyte or neutrophil, multiplied by the percentage of phagocytes engaged in phagocytosis [21, 22].

The baking yeast (S. cerevisiae) suspension was prepared as described previously [20, 21, 23]. Saccharomyces cerevisiae yeasts are phagocytosed via receptors. Phagocytosis may occur via pattern recognition receptors when receptors recognize directly conserved pathogen-associated molecular patterns (PAMPs) on the surface of the particle to be phagocytosed. In addition, phagocytosis may be facilitated by opsonins when internalization of the particle occurs through receptors to components of complement or via receptors to FcIgG [23]. Saccharomyces cerevisiae were used with or without previous incubation with fresh serum from the donor. In the first case, yeasts were opsonized by complement molecules and antibodies present in the fresh serum, which adhered on the yeast surface and phagocytosis occurred by complement receptors or by receptors to the Fc portion of immunoglobulin G (IgGFc receptors). When the yeasts were incubated with fetal calf serum, phagocytosis occurred via the pattern-recognition receptors of monocytes and neutrophils [23].

Production of superoxide anion

The nitro blue tetrazolium (NBT) salt reduction method [23] was used to evaluate the production of superoxide anion (O-). This reactive oxygen species reduces the NBT compound to an insoluble form, formazan, which is visualized by optic microscopy as a blue color in the cytoplasm of phagocytes.

Phagocytes adhered on the slide as described above were incubated with 0.05% NBT in Hanks-Tris (Sigma) solution for 20 min in a wet chamber at 37°C (baseline O- production). Stimulated superoxide anion production by phagocytes was evaluated after a suspension of S. cerevisiae was added at a ratio of 1 phagocyte/5 yeast per well and incubated for 20 min in a wet chamber at 37°C. The slides were washed, fixed with methanol, and stained with a solution of 1.4% safranin and 28.6% glycerol in distilled water. The results are expressed as the percentage of phagocytes (monocytes plus neutrophils) that reduced the NBT salt, and the percentage of reduction of NBT was quantified by optical microscopy individually for each patient. The total percent of phagocytes that reduced the NBT, percent of phagocytes phagocytosing S. cerevisiae that reduced or did not reduce NBT, and percent of phagocytes that were not in phagocytosis and reduced or did not reduce NBT were determined.

Statistical analysis

The results were evaluated by Bartlett’s test for equal variances and the Kolmogorov–Smirnov test for normally distributed data before comparative analysis. The data were evaluated by analysis of variance (ANOVA), followed by the Student–Newman-Keuls method or Kruskal-Wallis test and Dunn’s method to compare multiple unrelated samples of normally or non-normally distributed data, respectively. The Student’s t test was performed to compare two normal unrelated samples. For non-normal distributions, the Mann-Whitney test was used to compare two unrelated groups. GraphPad Prism 8.0 software (GraphPad, Inc., La Jolla, CA, USA) was used for statistical tests and graphical presentation of the data. Differences with a two-tailed value of p < 0.05 and 95% confidence intervals (CI) were considered as statistically significant.

Results

The demographic characteristics of the patients are shown in Table 1. Six patients who presented with acute respiratory infection at the examination and/or with non-specific CRS were excluded from the study group. Therefore, the investigation included 30 subjects. No correlation was observed between nutritional status and phagocytosis tests (Pearson correlation; p > 0.05).

Phagocytic capacity of neutrophils and monocytes

Phagocytosis by PAMPs

The percentage of neutrophils involved in phagocytosis was higher in the control group (14.8%) [95% confidence interval (CI): 10.44–27.78] than in the CF (1.5%, CI: -2.22–9.02) and in CF+CRS with NP (1.5%, CI: -1.77–9.83) groups [Kruskal-Wallis (KW); p = 0.0025 (5 yeast/cell)]. In a more concentrated proportion of yeasts (20 yeasts/neutrophil), the percentage of neutrophils was more involved in phagocytosis in the control group (26%, CI: 12.47–33.45) than in CF+CRS with NP (1.5%, CI: 0.07–1.524) (KW, p = 0.0005). Furthermore, the percentage of neutrophils engaged in phagocytosis in the CF+CRS without NP group (4.5%, CI: 3.33–5.36) was higher than in the CF+CRS with NP group (0.5%, CI: 0.07–1.524) (KW = 0.028) (Fig 1A1 and S1 Table). Moreover, the number of yeasts phagocytosed by neutrophils was higher in the control group (1.4, CI: 1.24–1.55) than in the CF group (1, CI: 0.96–1.07). In addition, the number of yeasts phagocytosed by neutrophils in CF (1, CI: 0.96–1.07) and CF+CRS with NP (1, CI: 0.42–1.70) were lower than in CF+CRS without NP (1.9, CI: 0.86–1.20) (KW = 0.048) (Fig 1A2). The PhI was also higher in the control group (18.8, CI:14.37–10.16) than in the CF (1.5, CI: -2.76–10.16) and CF+CRS with NP groups (2, CI: -1.3–10.22) (KW = 0.0014) in the evaluation of 5 yeasts/cell. When this was tested using 20 yeasts/cell, the PhI of the control group (20.8, CI: 13.66–37.67) was higher than the CF+CRS with NP group (1.5, CI: 0.25–2.51) (KW = 0.0128). In addition, the PhI was higher in the CF+CRS without NP group (5, CI: 0.87–8.32) than in the CF (1.5, CI: -1.71–5.21) and CF+CRS with NP groups (2, CI: 0.25–2.51) (KW = 0.0168) (Fig 1A3 and S1 Table).

Fig 1. Phagocytosis by neutrophils.

Fig 1

Phagocytosis of Saccharomyces cerevisiae cells by pathogen-associated molecular pattern A) and opsonin receptors (B) by blood peripheral neutrophils in children. Groups: cystic fibrosis (CF) n = 6; cystic fibrosis plus chronic rhinosinusitis and presenting nasal polyps (CF+CRS with NP) n = 6; cystic fibrosis plus chronic rhinosinusitis but without nasal polyps (CF+CRS without NP) n = 5; control group (n = 14). In the top, % of neutrophils involved in phagocytosis, in the middle, number of yeasts ingested by neutrophils and in the bottom phagocytic index. Significant results are shown by bar between groups. Values are presented as the median, quartiles, maximum, and minimum values. KW = Kruskal-Wallis.

We found no difference among groups when phagocytosis by monocytes was tested through the PAMPs (KW, p > 0.05) (Fig 2 and S1 Table).

Fig 2. Phagocytosis by monocytes.

Fig 2

Phagocytosis of Saccharomyces cerevisiae cells by pathogen-associated molecular pattern (A) and opsonin receptors (B) by blood peripheral monocytes in children. Groups: Cystic fibrosis (CF) n = 6; cystic fibrosis plus chronic rhinosinusitis and presenting nasal polyps (CF+CRS with NP) n = 6; cystic fibrosis plus chronic rhinosinusitis but without nasal polyps (CF+CRS without NP) n = 5; control group (n = 14). In the top, % of neutrophils involved in phagocytosis, in the middle, number of yeasts ingested by neutrophils and in the bottom, phagocytic index. Significant results are shown by bar between groups. Values are presented as the median, quartiles, maximum, and minimum values.

Phagocytosis facilitated by opsonins

For neutrophils, we observed a higher percentage of cells involved in phagocytosis (5 yeast/cell) in the control group (53%, CI: 51.74–73.55) than in the CF+CRS without NP group (36.8%, CI: 29.11–48.16) (KW, p = 0.0196) (Fig 1B1 and S2 Table). A reduced number of yeasts ingested by neutrophils (20 yeasts/cell) was also observed in all groups [CF = 1.7 (1.28–2.56); CF+CRS with NP = 1.7 (1.46–1.83); CF+CRS without NP = 1.6 (1.11–2.4)] compared to the control group = 2.6 (2.35–3.44) (ANOVA, p = 0.028) (Fig 1B2 and S2 Table). Moreover, the control group (198; CI: 167.4–272.4) showed a higher PhI than the CF (99.2; CI: -7.59–171.8) and CF+CRS with NP groups (97.1; CI: 67.32–139.4) (ANOVA, p = 0.0047) when tested using 20 yeasts/cell (Fig 1B3 and S2 Table).

For monocytes, we observed a larger number of yeasts ingested by monocytes (20 yeast/cell) in the control group (2.6; CI: 2.33–3.49) than in the CF+CRS with NP group (2.1; CI: 1.51–2.32) (KW = 0.0375 and t test) (Fig 2B2 and S2 Table). Evaluation of the PhI of monocytes facilitated by opsonins showed that the control group (102.5; CI: 82.83–107.4) had a higher PhI (5 yeasts/monocyte) than in all other groups [CF = 24.5 (15.9–81.18); CF+CRS with NP = 55.8 (9.27–78.56); CF+CRS without NP = 19.6 (13.33–44.86)] (ANOVA, p < 0.001) (Fig 2B3 and S2 Table).

Evaluation of superoxide anion production by phagocytes

Percentage of phagocytes producing superoxide anions at the basal production

The KW test followed by Dunn’s method showed that superoxide anion production by phagocytes obtained from participants with CRS with NP (43.5%; CI: 12.16–63.04) or CF (20.0%; CI: 6.310–51.29) had a lower median superoxide production than those produced by healthy participants (83.0%; CI: 66.69–89.24) (p = 0.0012). In contrast, there was no difference between the control and CRS without NP group (38.9%; CI: 19.65–68.61) (p > 0.05) (Fig 3A1).

Fig 3. Superoxide anion production.

Fig 3

Percentage of reduction of nitro blue tetrazolium by phagocytes obtained from peripheral blood of the control group (n = 14), cystic fibrosis group (CF; n = 5), cystic fibrosis + chronic rhinosinusitis with polyps group (CF+CRS with NP; n = 5), and cystic fibrosis + rhinosinusitis without polyps group (CF+CRS without NP; n = 6). Phagocytes were incubated with and without Saccharomyces cerevisiae yeasts to either stimulate or not stimulate superoxide anion production. Significant results are shown by * between groups. Values are presented as the median, quartiles, maximum, and minimum values.

Percentage of phagocytes involved in phagocytosis without production of superoxide anion

The median number of phagocytes involved in phagocytosis without O- production in all groups [CF = 31.5% (CI: 1-.61–67.43), CF+CRS with NP = 21.5% (CI: 7.91–34.05) or CF+CRS without NP = 27.5% (CI: 3.37–56.96)] was higher than that in the control group = 0.0% (p = 0.0001, CI: 0.003–1.817) (Fig 3B1).

Percentage of phagocytes involved in phagocytosis with superoxide anion production

The percentage of phagocytes involved in phagocytosis that produced superoxide anion was higher in the control group (74.0 ± 9.6%; CI: 68.14–79.78) than those observed in the CF (5.9 ± 4.1%; CI: 0.87–11.01), CF+CRS with NP (2.8 ± 3.7%; CI: 1.78–7.388), and CF+CRS without NP (9.2 ± 7.6%; CI: 1.198–17.20) groups (ANOVA; p < 0.02001) (Fig 3B2).

Percentage of phagocytes without phagocytosis or superoxide anion production

The percentage of phagocytes that did not exhibit phagocytosis nor superoxide anion production in the control group (1.5%, CI: 1.01–4.34) was lower than that in the other groups [CF = 35% (CI: 11.92–60.12); CF+CRS with NP = 41% (CI: 16.09–70.55); CF+CRS without NP = 21.75% (CI: 5.013–54.15)] (KW; p < 0.0001) (Fig 3C1).

Percentage of phagocytes without phagocytosis but produced superoxide radical

The median percentage of phagocytes that were not involved in phagocytosis but produced superoxide anions did not differ among groups [control = 23.25% (CI: 18.14–25.94); CF = 10.5% (CI: 2.97–34.70; CF+CRS with NP = 34.25% (CI: 12.08–54.29); CF+CRS without NP = 16.8% (CI: 1.91–60.25) (Fig 3C2).

Discussion

Our data showed that CF significantly impacts the phagocytosis rate and superoxide anion production by peripheral blood-derived neutrophils and monocytes, as determined by phagocytosis assay with S. cerevisiae [2123] and superoxide anion production tested by NBT reduction. This is the first study to compare this type of activity in neutrophils and monocytes in peripheral blood from patients with different CF CRS phenotypes. Because of the difficulty of investigating cell populations in the mucosa of the paranasal sinuses, neutrophils and monocytes originating in the bone marrow may reveal the behavior of leukocytes in the upper airways. Moreover, these results support that deficient CFTR is expressed in myeloid-derived cells [7].

We showed that neutrophils from patients with CF with or without CRS had lower PhIs both by lower engagement of neutrophils in phagocytosis and smaller number of phagocytosed yeasts. Interestingly, patients with CRS without NP showed an increased number of yeasts phagocytosed by the cells. According to Downey et al [27], comparison of gene expression in blood neutrophils from patients with CF and healthy controls showed that 62 genes were upregulated. However, none of these genes coded for adhesion molecules (ICAM-1 and 2), which may explain the lower capacity for yeast endocytosis by phagocytes when PAMPs and opsonins receptors were evaluated, as observed in our study. In addition, Bonfield et al7 showed that mice myeloid cells lacking CFTR failed to control Pseudomonas aeruginosa infection in animal models compared to that in normal CFTR groups. In fact, P. aeruginosa depends mainly on phagocytosis by neutrophils for its defense, which was impaired in all of our CF patients. These findings highlight that the innate inflammatory process may begin before infection, potentially as a result of the early clinical presentation of NP observed in children, even without P. aeruginosa colonization. These impaired neutrophil functions indicate that a primary defect in CF leukocytes plays a major role in the clinical phenotypes of CRS.

Other defects in the phagocytic activity of these cells in individuals with CF-related CRS may be related to the presence of intramucosal microcolonies in the nasal cavity, which are mainly formed by Staphylococcus aureus. Few inflammatory cells exist around these microcolonies [5]. This biofilm behaves as a less immunogenic bacterial surface [5], which may be associated with the lower phagocytosis capacity of phagocytes by opsonin receptors in patients with CF with CRS than in the control group, as per observations in peripheral blood samples.

CRsNP, CRSwNP and CF-NP are different disease entities with distinct cytokine, mediator, and cellular profiles [18, 28]. Among the different types of CRS, our data showed that neutrophils from patients with CF+CRS without NP endocytosed more yeasts than patients with CF and CF+CRS with NP. CRS related to CF is associated with upregulation of β-defensin 2 and Toll-like receptor 2. Furthermore, expression of the mannose receptor dominates the innate defense in non-CF NP [18]. The significantly different outcomes between the CRS groups in CF raise new questions about the pathophysiology of NP. Neutrophils and monocytes are plastic cells, and their physiological functions partially depend on their origin [10]. Our sample of 38% patients with CF with NP differed from the results of Schmitt et al [29] but agreed with those of Weber et al [30] observed in a Brazilian population. In addition to genetic factors, diversity in geographic, socioeconomic, and nutritional status may influence the innate immunity of subjects with CF [28]. Other studies of our population are necessary to support the plasticity of these leukocytes in the peripheral blood without demographic and socioeconomic bias.

In the absence of effective phagocytosis, some phagocytes showed enhanced superoxide anion production, suggesting that in addition to phagocytosis deficiency, which prevents pathogen clearance, inadequate superoxide anion production without effective phagocytosis may enhance tissue lesions caused by inadequate enhancement in radical oxygen production [23]. Our data showed that these unbalanced responses resulted in higher production of superoxide anions without phagocytosis in all CF studied (Fig 3C1). This pro-inflammatory status was also observed as the higher percentage of S. cerevisiae cell ingestion. Radical oxygen species have various antibacterial, antifungal, and antiviral effects, although some of these substances are tonically secreted [23] and are upregulated even in the absence of pathogens. In the control group, the percentage of phagocytes that participated in phagocytosis with the production of superoxide anions was higher, demonstrating a more balanced function of phagocytes. Our results suggest that superoxide anions generated by phagocytes play an essential role in upper airway innate immunity in CF, without significant differences between CRS phenotypes.

A limitation of our study was the small number of participants. Furthermore, the presence of some comorbidities and liposoluble vitamins and hemoglobin levels were not controlled. In addition, the severity of lung disease and nutritional status were only evaluated by classifying the digital clubbing and percentile by age, respectively. Although no difference in phagocytic function was observed in malnourished children, a more detailed analysis involving chest scans and determination of the corporal composition, such as the muscle and fat body distribution, may reveal a correlation with phagocytosis in these individuals.

In conclusion, patients with CF with and without CRS, exhibited impairments in phagocytosis by neutrophils and monocytes. Strategies for improving myeloid cell health and function are needed. Future research on innate immunity diagnoses and treatment is necessary.

Supporting information

S1 Table. Phagocytosis of Saccharomyces cerevisiae cells by pathogen-associated molecular pattern receptors in the peripheral leukocytes of children; values are expressed as median.

(DOCX)

S2 Table. Phagocytosis of Saccharomyces cerevisiae by opsonin receptors in the peripheral leukocytes of children; the values are expressed as median values.

(DOCX)

S1 File

(PDF)

S2 File

(PDF)

S3 File

(PDF)

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

The material used in this research came from the Cellular Immunology Laboratory’s own resources provided by Faculty of Medicine, University of Brasilia and self-donation of authors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors received no specific funding for this work.

References

  • 1.Bruscia EM, Bonfield TL. Cystic fibrosis lung immunity: The role of the macrophage. J Innate Immun. 2016;8(6):550–563. doi: 10.1159/000446825 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyposis 2020. Rhinology. 2020; Suppl.20:1–464. doi: 10.4193/Rhin20.600 [DOI] [PubMed] [Google Scholar]
  • 3.Belchamber KBR, Donnelly LE. Macrophage dysfunction in respiratory disease. Results Probl. Cell Differ. 2017;62:299–313. doi: 10.1007/978-3-319-54090-0_12 [DOI] [PubMed] [Google Scholar]
  • 4.Giddings O, Esther CR. Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers. Pediatr Pulmonol. 2017;52:S21–S28. doi: 10.1002/ppul.23768 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kim RJ, Park L, Wood AJ, Yin T, Jain R, Douglas RG. Chronic rhinosinusitis and cystic fibrosis: the interaction between sinus bacteria and mucosal immunity. Int. Forum Allergy Rhinol. 2015;5(5):380–385. doi: 10.1002/alr.21431 [DOI] [PubMed] [Google Scholar]
  • 6.Leuer L, Krill A, Wilkens H, Wagenpfeil G, Bischoff M, Meier C, et al. The Phagocytosis of blood leukocytes from cystic fibrosis patients is not impaired in general. Lung. 2019;198:235–239 doi: 10.1007/s00408-019-00290-9 [DOI] [PubMed] [Google Scholar]
  • 7.Bonfield TL, Hodges CA, Cotton CU. Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection. J Leukoc Biol. 2012;92: 1111–1122. 10.1189/jlb.0412188 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yoshimura K, Nakamura H, Trapnell BC, Chu CS, Dalemans W, Pavirani A, et al. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res. 1991; 19:5417–5423. doi: 10.1093/nar/19.19.5417 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Del Porto P, Cifani N, Guarnieri S, Di Domenico EG, Mariggiò MA, Spadaro F, et al. Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS One. 2011;6,e19970. 10.1371/journal.pone.0019970 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Simonin-Le Jeune K, Le Jeune A, Jouneau S, Belleguic C, Roux PF, Jaguin M, et al. Impaired functions of macrophage from cystic fibrosis patients: CD11b, TLR-5 decrease and sCD14, inflammatory cytokines increase. PLoS One. 2013;8, e75667. 10.1371/journal.pone.0075667 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lévêque M, Trionnaire SL, Porto PD, Martin-Chouly C. The impact of impaired macrophage functions in cystic fibrosis disease progression. J Cystic Fibros. 2017;16:443–53. doi: 10.1016/j.jcf.2016.10.011 [DOI] [PubMed] [Google Scholar]
  • 12.Hamilos DL. Chronic rhinosinusitis in patients with cystic fibrosis. J Allergy Clin Immunol Pract. 2016;4:605–612. doi: 10.1016/j.jaip.2016.04.013 [DOI] [PubMed] [Google Scholar]
  • 13.Tarique AA, Sly PD, Cardenas DG, Luo L, Stow JL, Scott C, et al. Differential expression of genes and receptors in monocytes from patients with cystic fibrosis. J Cystic Fibros. 2019;18(3):342–348. doi: 10.1016/j.jcf.2018.07.012 [DOI] [PubMed] [Google Scholar]
  • 14.Nichols DP, Chmiel JF. Inflammation and its genesis in cystic fibrosis. Pediatr Pulmonol. 2015:50 Suppl 40:S39–56. doi: 10.1002/ppul.23242 [DOI] [PubMed] [Google Scholar]
  • 15.Zhang S, Shrestha CL, Kopp BT. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function. Sci Rep. 2018;8:17066. doi: 10.1038/s41598-018-35151-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kang SH, Dalcin PT, Piltcher OB, Migliavacca RO. Chronic rhinosinusitis and nasal polyposis in cystic fibrosis: update on diagnosis and treatment. J Bras Pneumol. 2015;41(1):65–76. doi: 10.1590/S1806-37132015000100009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Claeys S, Van Hoecke H, Holtappels G, Gevaert P, De Belder T Verhasselt B, et al. Nasal polyps in patients with and without cystic fibrosis: a differentiation by innate markers and inflammatory mediators. Clin Exp Allergy. 2005; 35(4):467–472. doi: 10.1111/j.1365-2222.2005.02215.x [DOI] [PubMed] [Google Scholar]
  • 18.Huvenne W, van Bruaene N, Zhang N, Zele TV, Patou J, Gevaert P, et al. Chronic rhinosinusitis with and without nasal polyps: what is the difference? Curr Allergy Asthma Rep. 2009;9(3):213–220. doi: 10.1007/s11882-009-0031-4 [DOI] [PubMed] [Google Scholar]
  • 19.Deriy LV, Gomez EA, Zhang G, Shevchenko PV, Bindokas V, Nelson DJ, et al. Disease-causing mutations in the cystic fibrosis transmembrane conductance regulator determine the functional responses of alveolar macrophages. J Biol Chem. 2009;284:35926–35938. doi: 10.1074/jbc.M109.057372 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Naiff PF, Carneiro VMA, Guimarães MDCM, Bezerra ACB, Oliveira MS, Couto SCP, et al. Mechanical periodontal therapy recovered the phagocytic function of monocytes in periodontitis. Int J Dent. 2020;2020:8636795. doi: 10.1155/2020/8636795 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Muniz-Junqueira MI, Peçanha LM, Silva-Filho VL, Cardoso MCA, Tosta CE. Novel microtechnique for assessment of postnatal maturation of the phagocytic function of neutrophils and monocytes. Clin Diagn Lab Immunol. 2003;10:1096–1102. doi: 10.1128/cdli.10.6.1096-1102.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Muniz-Junqueira MI, Prata A, Tosta CE. Phagocytic and bactericidal function of mouse macrophages to Salmonella typhimurium in schistosomiasis mansoni. Am J Trop Med Hyg. 1992;46:132–136. doi: 10.4269/ajtmh.1992.46.132 [DOI] [PubMed] [Google Scholar]
  • 23.da Silva-Martins CL, Couto SC, Muniz-Junqueira MI. Inhaled corticosteroid treatment for 6 months was not sufficient to normalize phagocytosis in asthmatic children. Clin Transl Allergy. 2013;3(1):28. doi: 10.1186/2045-7022-3-28 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. 64th WMA General Assembly WMA, 2013. [PubMed]
  • 25.WHO. Working Group on Infant Growth. An evaluation of infant growth: the use and interpretation of anthropometry in infants. Bull. World Health Org, 1995; 73(2):165–174. [PMC free article] [PubMed] [Google Scholar]
  • 26.Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg. 1997; 117:S35–40. doi: 10.1016/s0194-5998(97)70005-6 [DOI] [PubMed] [Google Scholar]
  • 27.Downey DG, Bell SC, Elborn JS. Neutrophils in cystic fibrosis. Thorax. 2009;64(1):81–88. doi: 10.1136/thx.2007.082388 [DOI] [PubMed] [Google Scholar]
  • 28.Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138(5):1344–1353. doi: 10.1016/j.jaci.2016.05.041 [DOI] [PubMed] [Google Scholar]
  • 29.Schmitt WJ Neaville W Pongdee T. Prevalence of cystic fibrosis in children who present with nasal polyposis, J Allergy Clin Immunol. 2005; 115(2):S16. [Google Scholar]
  • 30.Weber SA, Iyomasa RM, Corrêa CC, Florentino WNM, Ferrari GF. Nasal polyposis in cystic fibrosis: follow-up of children and adolescents for a 3-year period. Braz J Otorhinolaryngol. 2017;83:677–682. doi: 10.1016/j.bjorl.2016.09.005 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Mrinmoy Sanyal

24 Mar 2022

PONE-D-21-40067Alterations in innate immune responses of patients with chronic rhinosinusitis related to cystic fibrosisPLOS ONE

Dear Dr. Rezende,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We believe addressing the reviewer's comments will significantly improve the quality and readability of the manuscript. Please note that the detail comments of Reviewer # 1 are an attachment (Word file). Please download the comments and address them.

Please submit your revised manuscript by May 08 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Mrinmoy Sanyal, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“Unfunded study”

At this time, please address the following queries:

a)        Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b)        State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c)        If any authors received a salary from any of your funders, please state which authors and which funders.

d)        If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

********** 

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The findings in the manuscript has been well presented, providing statistical analyses as well as clear explanation of the methods implemented. Overall the manuscript is easy to follow. I have attached my comments for further perusal to help improve the manuscript.

Reviewer #2: REVIEW SUMMARY

In this study Rezende et al. aims to understand how the innate immune system’s function changes in patients of cystic fibrosis and compared it with a sub-group who have developed chronic rhinosinusitis. This manuscript was assessed for the 7 criteria for publication in PLoS One. Rezende et al. present results of original research that have not been published elsewhere. Experiments performed, statistical analyses meet high technical standard and are described in sufficient detail. The analytical rigor of the authors is demonstrated by the fact that they perform corrections for normally and non-normally distributed data. The authors also adhere to reporting and ethics standards — all volunteers and their parents/guardians signed consent forms.

However, there are deficiencies in conclusions drawn from the results, and on article presentation/reporting. The authors over-extend when drawing conclusions from their results. In the introduction section in the abstract, instead of focusing on the gap in knowledge statements about the field of cystic fibrosis is made that is unambiguous and not entirely accurate. In addition, the results section and figure panels are structured in a difficult to interpret manner.

As such, in its current form this manuscript cannot be recommended for publication. Detailed comments are below.

MAJOR COMMENTS ON CONCLUSION

1. In the introduction section (Page 7, last paragraph), the authors write “… we evaluated whether neutrophiles and monocytes that circulate in the peripheral blood participate directly in inflammatory activity in the paranasal sinuses”. This is incorrect. In vitro assessment of phagocytotic activity and superoxide anion production of neutrophiles and monocytes cannot be used to determine whether these cells participate directly in inflammatory activity in the paranasal sinuses. This is particularly true because these immune cells were isolated from peripheral blood collected in vacuum tubes, presumably through venous blood draw from the arm (Materials and Methods section, Page 9, 3rd paragraph). This conclusion is incorrect.

2. In the highlights section (Page 3, 2nd bullet point), the authors write “Chronic Rhinosinusitis related to Cystic Fibrosis group has impaired leukocytes compared to control group”. This is an over-extension of the results. The authors measure in vitro phagocytotic ability of neutrophiles and monocytes (Y-axis labels, Fig 1 and 2), not for leukocytes that include B-cells, cytotoxic T-cells. Hence this statement is incorrect and does not accurately reflect the results.

MAJOR COMMENTS ON ARTICLE PRESENTATION/REPORTING

1. The results section is structured in a difficult to interpret manner. Numbering is not used, and nesting of sub-sections is achieved through italicizing. Also, each paragraph in the “Evaluation of superoxide production by phagocytes” section has its own sub-heading. This is not required and adds unnecessary word count to the manuscript.

2. In the abstract the authors write “The role of leukocytes in the innate immune system of children with cystic fibrosis (CF) is unclear, mainly when associated with chronic rhinosinusitis”. The sentence should be constructed in an unambiguous manner that aligns with the experiments conducted in this paper. As written, the sentence insinuates that the role of leukocytes in pediatric patients of cystic fibrosis is unknown.

MINOR COMMENTS ON ARTICLE PRESENTATION/REPORTING

1. Figures are labeled in as A1, B2. The panel naming should be alphabetical. The 3 x 2 grid structure of the figure panels is enough to segment the experimental results and orient the reader.

2. References 17, 18 and 7, 11 in the introduction section (Page 6, 3rd paragraph, first sentence) are misplaced/swapped. This compound statement is supported by two sets of references, which support the opposite halves of the sentence. “The genetic basis of CF has been clearly established, …” should be supported by references 17, 18 and not 7, 11. The opposite is true for the second part of that sentence. “… but no specific mutation is correlated with the impact on the phagocytic activity of neutrophils and monocytes” should be supported by 7, 11 not 17, 18.

********** 

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Reviewer Comments.docx

PLoS One. 2022 May 6;17(5):e0267986. doi: 10.1371/journal.pone.0267986.r002

Author response to Decision Letter 0


3 Apr 2022

Re: Manuscript Ref.: PONE-D-21-40067. “Alterations in innate immune responses of patients with chronic rhinosinusitis related to cystic fibrosis”

Comments from authors

We are very grateful to the reviewers for their suggestions, which greatly improved the quality of our manuscript.

Reviewer 1

“The findings in the manuscript has been well presented, providing statistical analyses as well as clear explanation of the methods implemented. Overall the manuscript is easy to follow. I have attached my comments for further perusal to help improve the manuscript.”

“The article by Gustavo Lara Rezende and colleagues, “Alterations in innate immune responses of patients with chronic rhinosinusitis related to cystic fibrosis”, offers insights on the role of monocytes and neutrophils in CF +/- CRS+/-NP and importance for the need of more diagnostic and treatments options for this illness. Overall, the study has been well-executed, and the manuscript well written providing explanations and background information to make the manuscript an enjoyable and easy to understand read.

I have minor suggestions to improve the manuscript”.

Query 1:

Materials and Methods

Formatting:

Pg.9 – ‘In addition, endoscopic signs… meatus or were necessary to define CRS’. The word “OR” should be deleted.

Answer 1:

Thank you, “OR” was deleted.

Query 2:

Pg. 10 – Second paragraph… ‘Saccharomyces cerevisiae yeast are phagocytosed via receptors. Phagocytosis…. Align the paragraph accordingly.

Answer 2:

The paragraph was aligned.

Query 3.

Table 1: As transplant patients are given immunosuppressive (IS) drugs, it would be nice to mention the # of years post-transplant for the specific subject under the CF+CRS with NP group and clearly specify whether this subject was still on any IS drugs or not to infer that any alterations in this subject’s immune system was not contributed from post-transplant treatment.

Answer 3: Thank you for this important observation. It was added: “8th year after liver transplantation because of congenital biliary atresia, without immunosuppressive drugs at the moment.” Please, see in Table 1

Query 4:

Figures 1 and 2:

It would be better to rename A, B and C as top, middle and bottom panel respectively to avoid confusion with the figure names A1, A2, etc. and as “A, B and C” are not stated on the figures.

Answer 4:

In the figures 1 and 2, it was included the letter “A” for phagocytosis by molecular patters and “B” for phagocytosis by opsonins. In the legend, the figures were identified by “top” for % of neutrophils involved in phagocytosis, “middle” for number of yeasts ingested by neutrophils and “bottom” for phagocytic index. Please, see in the figures 1 and 2.

Query 5:

Figure 1A3- under 20 yeasts/neutrophils there is an additional undefined box plot along with a statistical line after CF+CRS without NP. Please clarify.

Answer 5:

Thank you. This was a mistake that was now removed.

Query 6:

Supplementary Table 1 & 2: Kindly explain what you mean by ‘*values different from their respective control’?

Answer 6:

It means that the values are p<0,05. It was included in the text. Please, see in S1 e 2 Tables.

Query 7:

Supplementary Table 2: Both CF+CRS with/without NP have the same number of yeasts ingested by monocytes 2.1 (20 years per cell). Yet a statistical difference is only observed for Ctrl vs CF+CRS with NP and not Ctrl vs CF+CRS without NP. Could you provide some insights on the same?

Answer 7:

Please, observe in the figure 2B2 that although the median is the same for both patients CP+CRS with or without NP, the box-plot for patients with NP shows the interquartile range and the minimum value below that of patients without NP. In addition, statistical test showed that the number of yeasts ingested by monocytes of control group was higher than that of CP+CRS with NP. However, this difference was not significant for the patients without NP.

Reviewer 2

“In this study Rezende et al. aims to understand how the innate immune system’s function changes in patients of cystic fibrosis and compared it with a sub-group who have developed chronic rhinosinusitis. This manuscript was assessed for the 7 criteria for publication in PLoS One. Rezende et al. present results of original research that have not been published elsewhere. Experiments performed, statistical analyses meet high technical standard and are described in sufficient detail. The analytical rigor of the authors is demonstrated by the fact that they perform corrections for normally and non-normally distributed data. The authors also adhere to reporting and ethics standards — all volunteers and their parents/guardians signed consent forms.

However, there are deficiencies in conclusions drawn from the results, and on article presentation/reporting. The authors over-extend when drawing conclusions from their results. In the introduction section in the abstract, instead of focusing on the gap in knowledge statements about the field of cystic fibrosis is made that is unambiguous and not entirely accurate. In addition, the results section and figure panels are structured in a difficult to interpret manner.

As such, in its current form this manuscript cannot be recommended for publication. Detailed comments are below.

MAJOR COMMENTS ON CONCLUSION

Query 1

In the introduction section (Page 7, last paragraph), the authors write “… we evaluated whether neutrophiles and monocytes that circulate in the peripheral blood participate directly in inflammatory activity in the paranasal sinuses”. This is incorrect. In vitro assessment of phagocytotic activity and superoxide anion production of neutrophiles and monocytes cannot be used to determine whether these cells participate directly in inflammatory activity in the paranasal sinuses. This is particularly true because these immune cells were isolated from peripheral blood collected in vacuum tubes, presumably through venous blood draw from the arm (Materials and Methods section, Page 9, 3rd paragraph). This conclusion is incorrect.

Answer 1:

We agree with the reviewer. It was changed the word “directly” to “indirectly”. Please, see in the introduction, last paragraph

Query 2:

In the highlights section (Page 3, 2nd bullet point), the authors write “Chronic Rhinosinusitis related to Cystic Fibrosis group has impaired leukocytes compared to control group”. This is an over-extension of the results. The authors measure in vitro phagocytotic ability of neutrophiles and monocytes (Y-axis labels, Fig 1 and 2), not for leukocytes that include B-cells, cytotoxic T-cells. Hence this statement is incorrect and does not accurately reflect the results.

Answer 2: We agree with the reviewer. For better comprehension, it was changed “leukocytes” to “neutrophils and monocytes”. Please, see in highlights.

MAJOR COMMENTS ON ARTICLE PRESENTATION/REPORTING

Query 3:

1. The results section is structured in a difficult to interpret manner. Numbering is not used, and nesting of sub-sections is achieved through italicizing. Also, each paragraph in the “Evaluation of superoxide production by phagocytes” section has its own sub-heading. This is not required and adds unnecessary word count to the manuscript.

Answer 3: The results section was sub-sectioned again according to the PLOS ONE style templates. We would prefer that remain the sub-heading of subsections to make clearer the topic. These sub-sections were formatted in Level 2 headings, bold type 16pt and Level 3 headings, bold type, 14pt font as style templates instructions.

Query 4:

2. In the abstract the authors write “The role of leukocytes in the innate immune system of children with cystic fibrosis (CF) is unclear, mainly when associated with chronic rhinosinusitis”. The sentence should be constructed in an unambiguous manner that aligns with the experiments conducted in this paper. As written, the sentence insinuates that the role of leukocytes in pediatric patients of cystic fibrosis is unknown.

Answer 4:

Thank you for the observation. The sentence was changed to make clearer: “The role of phagocytes of children with cystic fibrosis (CF) associated with different phenotypes of chronic rhinosinusitis (CRS) is unclear.” Please see in abstract:

MINOR COMMENTS ON ARTICLE PRESENTATION/REPORTING

Query 5:

1. Figures are labeled in as A1, B2. The panel naming should be alphabetical. The 3 x 2 grid structure of the figure panels is enough to segment the experimental results and orient the reader.

Answer 5: The identification in the legends of the figures 1 and 2 were changed “top” for % of neutrophils involved in phagocytosis, “middle” for number of yeasts ingested by neutrophils and “bottom” for phagocytic index. However, we would prefer that the labels A1, A2, etc. remain to facilitate the indication of the figures in the text in results

Query 6

2. References 17, 18 and 7, 11 in the introduction section (Page 6, 3rd paragraph, first sentence) are misplaced/swapped. This compound statement is supported by two sets of references, which support the opposite halves of the sentence. “The genetic basis of CF has been clearly established, …” should be supported by references 17, 18 and not 7, 11. The opposite is true for the second part of that sentence. “… but no specific mutation is correlated with the impact on the phagocytic activity of neutrophils and monocytes” should be supported by 7, 11 not 17, 18.

Answer 6:

Thank you. The order of references was changed in the manuscript. Please, see in the Introduction, 3rd paragraph.

Attachment

Submitted filename: Response to Reviewers 3April22.docx

Decision Letter 1

Mrinmoy Sanyal

20 Apr 2022

Alterations in innate immune responses of patients with chronic rhinosinusitis related to cystic fibrosis

PONE-D-21-40067R1

Dear Dr. Rezende,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Mrinmoy Sanyal, PhD

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors has addressed all the comments of the reviewer and revised the manuscript as required.

Reviewer #2: The authors have addressed the major concerns that were raised. Regarding the points on article presentation/reporting, it would be preferable if the editorial team took that decision since they are more experienced in such decisions.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Acceptance letter

Mrinmoy Sanyal

28 Apr 2022

PONE-D-21-40067R1

Alterations in innate immune responses of patients with chronic rhinosinusitis related to cystic fibrosis

Dear Dr. Rezende:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Mrinmoy Sanyal

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Phagocytosis of Saccharomyces cerevisiae cells by pathogen-associated molecular pattern receptors in the peripheral leukocytes of children; values are expressed as median.

    (DOCX)

    S2 Table. Phagocytosis of Saccharomyces cerevisiae by opsonin receptors in the peripheral leukocytes of children; the values are expressed as median values.

    (DOCX)

    S1 File

    (PDF)

    S2 File

    (PDF)

    S3 File

    (PDF)

    Attachment

    Submitted filename: Reviewer Comments.docx

    Attachment

    Submitted filename: Response to Reviewers 3April22.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES